EP0205336A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Oral sustained release pharmaceutical preparation
Assignee: Teijin Ltd
•
Filing: 1986-06-10
•
Granted: —
•
Expires: 2006-06-10
Abstract
Abstract This invention is concerned with an oral sustained release pharmaceutical preparation which is prepared as a pharmaceutical preparation comprising lower alkyl ether of cellulose, polyacrylic acid or its pharmaceutically acceptable salt, and active drugs, or a pharmaceutical preparation comprising lower alkyl ether of cellulose, polyacrylic acid or its pharmaceutically acceptable salt, and active drugs together with a foaming agent, so that it may release the active drugs by such slow degrees in the stomach or the intestinal tract as to make it possible to provide an adequate supply of active drugs in enough concentration to display their therapeutic value for many hours.
Inventors
- 👤 Hiroshi Ikura
- 👤 Yoshiki Suzuki
- 👤 Tsuneji Nagai
- 👤 Yoshiharu Machida
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-03 12:32
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0053; A61K9/0065; A61K9/20; A61K9/2004; A61K9/2022; A61K9/2027; A61K9/205; A61K9/2054
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
21 words
An oral sustained release pharmaceutical preparation comprising lower alkyl ether of cellulose, polyacrylic acid or its pharmaceutically acceptable salt, and drug.
Claim 2
Dependent Claim
21 words
An oral sustained release pharmaceutical preparation comprising lower alkyl ether of cellulose, polyacrylic acid or its pharmaceutically acceptable salt, and drug.
Claim 3
Dependent Claim
38 words
The oral sustained release pharmaceutical preparation according to Claim 1, wherein 0.1 to 1000 parts by weight of polyacrylic acid or its pharmaceutically acceptable salt is used against 10 parts by weight of lower alkyl ether of cellulose.
Claim 4
Dependent Claim
21 words
The oral sustained release pharmaceutical preparation according to Claim 1, wherein the dosage form is a granular pilute, tablet, or capsule.
Claim 5
Dependent Claim
25 words
The oral sustained release pharmaceutical preparation according to Claim 1, wherein the particle size of the granular pilule ranges from 0.5 mm to 2 mm.
Claim 6
Dependent Claim
59 words
The oral sustained release pharmaceutical preparation according to Claim 1, wherein said drug is any of drugs for gastrointestinal diseases, drugs for central nervous system, antiallergic agents and antihistamic agents, drugs for circulatory system, drugs for respiratory diseases, hormone drugs and hormone controling drugs, drugs for urinary and genital organs, metabolic drugs, drugs for tumor, antibiotics and chemotherapeutic agents.
Claim 7
Dependent Claim
32 words
The oral sustained release pharmaceutical preparation according to Claim 1, wherein a forming agent is used along with said lower aklyl ether of cellulose and polyacrylic acid or its pharmaceutically acceptable salt.
Claim 8
Dependent Claim
44 words
The oral sustained release pharmaceutical preparation according to Claim 6, wherein the foaming agent is used in an amount ranging from 10 to 50% by weight against the total weight of lower alkyl ether of cellulose and polyacrylic acid or its pharmaceutically acceptable salt.
Claim 9
Dependent Claim
28 words
The oral sustained release pharmaceutical preparation according to Claim 6, wherein said foaming agent is carbonate, bicarbonate, or a mixture of an organic acid and carbonate or bicarbonate.
Claim 10
Dependent Claim
27 words
A process for producing an oral sustained release pharmaceutical preparation comprising simply mixing lower alkyl ether of cellulose, polyacrylic acid or its pharmaceutically acceptable salt, and drug.
Claim 11
Dependent Claim
27 words
A process for producing an oral sustained release pharmaceutical preparation comprising simply mixing lower alkyl ether of cellulose, polyacrylic acid or its pharmaceutically acceptable salt, and drug.
Claim 12
Dependent Claim
39 words
The process for producing an oral sustained release pharmaceutical preparation according to Claim 9, wherein the process comprises simply mixing lower alkyl ether of cellulose, polyacrylic acid or its pharmaceutically acceptable salt, and drug together with a foaming agent.
Claim 13
Independent Claim
46 words
A method of administering the drug, which method comprises orally administering a pharmaceutical preparation made of lower alkyl ether of cellulose, polyacrylic acid or its pharmaceutically acceptable salt, and drug, thus allowing the parmaceutical preparation to release the drug gradually in the stomach or the intestinal-tract.
Claim 14
Independent Claim
46 words
A method of administering the drug, which method comprises orally administering a pharmaceutical preparation made of lower alkyl ether of cellulose, polyacrylic acid or its pharmaceutically acceptable salt, and drug, thus allowing the parmaceutical preparation to release the drug gradually in the stomach or the intestinal-tract.
Claim 15
Dependent Claim
31 words
The method of administering the drug according to Claim 11, wherein a foaming agent is used together with lower alkyl ether of cellulose and polyacrylic acid or its pharmaceutically acceptable salt.
Claim 16
Dependent Claim
42 words
The use of the pharmaceutical preparation made of lower alkyl ether of cellulose, polyacrylic acid or its pharmaceutically acceptable salt, and drug by oral administration to allow the pharmaceutical preparation to release the drug gradually in the stomach or the intestinal tract.
Claim 17
Dependent Claim
42 words
The use of the pharmaceutical preparation made of lower alkyl ether of cellulose, polyacrylic acid or its pharmaceutically acceptable salt, and drug by oral administration to allow the pharmaceutical preparation to release the drug gradually in the stomach or the intestinal tract.
Claim 18
Dependent Claim
32 words
The use of the pharmaceutical preparation according to Claim 13, wherein said lower alkyl ether of cellulose and polyacrylic acid or its pharmaceutically acceptable salt are used together with a foaming agent.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.